Level Bio Past Earnings Performance

Past criteria checks 0/6

Level Bio's earnings have been declining at an average annual rate of -54.3%, while the Life Sciences industry saw earnings growing at 26.7% annually. Revenues have been growing at an average rate of 7.4% per year.

Key information

-54.3%

Earnings growth rate

-52.4%

EPS growth rate

Life Sciences Industry Growth31.8%
Revenue growth rate7.4%
Return on equity-253.9%
Net Margin-51.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?

Jun 02
Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?

Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?

Feb 10
Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?

I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With Ease

Nov 03
I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With Ease

AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected

Aug 18
AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected

Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?

Mar 07
Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?

Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?

Nov 22
Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?

Revenue & Expenses Breakdown

How Level Bio makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NGM:LEVBIO Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2424-12220
31 Mar 2423-11210
31 Dec 2326-9200
30 Sep 2330-5190
30 Jun 2329-4160
31 Mar 2330-4160
31 Dec 2234-2160
30 Sep 2236-2160
30 Jun 2238-1210
31 Mar 22485160
31 Dec 21445120
30 Sep 21385150
30 Jun 2136580
31 Mar 2127280
31 Dec 2024280
30 Sep 2022180
30 Jun 2021180
31 Mar 2020080
31 Dec 1917-180
30 Sep 1918-190
30 Jun 1919-190
31 Mar 1918-190
31 Dec 1818-190
30 Sep 1818-1110
30 Jun 1818-2110
31 Mar 1820-3110
31 Dec 1723-1110
30 Sep 1726090
30 Jun 1730190
31 Mar 1729290
31 Dec 1627190
30 Sep 1626190
30 Jun 1624190
31 Mar 1624190
31 Dec 1524190
30 Sep 1522080
30 Jun 1522-180
31 Mar 1522-180
31 Dec 1421-180
30 Sep 1422070
30 Jun 1422070
31 Mar 1421070
31 Dec 1321-170

Quality Earnings: LEVBIO is currently unprofitable.

Growing Profit Margin: LEVBIO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LEVBIO is unprofitable, and losses have increased over the past 5 years at a rate of 54.3% per year.

Accelerating Growth: Unable to compare LEVBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LEVBIO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-13%).


Return on Equity

High ROE: LEVBIO has a negative Return on Equity (-253.87%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies